Parallel Advisors, LLC Karuna Therapeutics, Inc. Transaction History

Parallel Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$161.01 - $317.85 $7,245 - $14,303	45 Added 23.32%	238 $75,000
Q2 2023 May 20, 2024	BUY	$176.32 - $240.22 $705 - $960	4 Added 2.12%	193 $41,000
Q2 2023 Aug 04, 2023	BUY	$176.32 - $240.22 $705 - $960	4 Added 2.12%	193 $41,000
Q1 2023 May 20, 2024	BUY	$161.33 - $204.36 $30,491 - $38,624	189 New	189 $34,000
Q1 2023 Apr 25, 2023	SELL	$161.33 - $204.36 $483 - $613	-3 Reduced 1.56%	189 $34,000
Q4 2022 Feb 03, 2023	BUY	$191.53 - $236.82 $32,560 - $40,259	170 Added 772.73%	192 $37,000
Q3 2022 Nov 10, 2022	BUY	$123.79 - $277.42 $371 - $832	3 Added 15.79%	22 $5,000
Q2 2022 Aug 01, 2022	BUY	$93.97 - $143.33 $1,785 - $2,723	19 New	19 $2,000
Q1 2022 Apr 28, 2022	SELL	$98.9 - $132.37 $98 - $132	-1 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$110.64 - $159.4 $110 - $159	1 New	1 $0
Q4 2020 Feb 02, 2021	SELL	$75.23 - $109.23 $373,516 - $542,326	-4,965 Closed	0 $0
Q2 2020 Jul 16, 2020	BUY	$62.14 - $117.21 $308,525 - $581,947	4,965 New	4,965 $553,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.